ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
71,087.45
-0.51%
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs Yen
156.212
-0.11%
Brent Oil
82.445
-1.30%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Gilead Sciences Inc (GILD)

  7. Gilead Sciences Inc (GILD) ニュース

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:GILD
日付受信時刻ニュースソース見出しコード企業名
2024/05/1821 : 30Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
2024/05/1423 : 09Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1006 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1005 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
2024/05/1005 : 05Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramNASDAQ:GILDGilead Sciences Inc
2024/05/1004 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/1004 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
2024/05/0905 : 58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GILDGilead Sciences Inc
2024/05/0721 : 30Business WireGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024NASDAQ:GILDGilead Sciences Inc
2024/05/0105 : 05Business WireGilead Sciences to Present at Upcoming Investor ConferencesNASDAQ:GILDGilead Sciences Inc
2024/04/2621 : 00Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIVNASDAQ:GILDGilead Sciences Inc
2024/04/2620 : 47IH Market NewsExxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in EarningsNASDAQ:GILDGilead Sciences Inc
2024/04/2605 : 02Business WireGilead Sciences Announces First Quarter 2024 Financial ResultsNASDAQ:GILDGilead Sciences Inc
2024/04/2520 : 53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:GILDGilead Sciences Inc
2024/04/0905 : 05Business WireGilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:GILDGilead Sciences Inc
2024/03/2821 : 30Business WireFDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixNASDAQ:GILDGilead Sciences Inc
2024/03/2820 : 00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
2024/03/2820 : 00GlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:GILDGilead Sciences Inc
2024/03/2222 : 18Business WireGilead Sciences Announces Completion of Acquisition of CymaBayNASDAQ:GILDGilead Sciences Inc
2024/03/1908 : 29Business WireCenter for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink GrantNASDAQ:GILDGilead Sciences Inc
2024/03/1121 : 34Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:GILDGilead Sciences Inc
2024/03/1121 : 24Business WireGilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender OfferNASDAQ:GILDGilead Sciences Inc
2024/03/0706 : 30Business WireBiktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and ComorbiditiesNASDAQ:GILDGilead Sciences Inc
2024/03/0700 : 25Business WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NASDAQ:GILDGilead Sciences Inc
2024/03/0622 : 00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:GILDGilead Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:GILD

最近閲覧した銘柄

NYSE
DIS
Walt Disney
AMEX
XLF
Financial Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
AXP
American Express
NASDAQ
AAPL
Apple
COIN
ETHUSD
Ethereum
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
FX
USDJPY
US Dollar vs Yen
CCOM
US100
US Tech 100
AMEX
XLE
Energy Select Sector SPDR
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有